Precision System Science Co.,Ltd AI Stock Analysis
Want to see JP:7707 full AI Analyst Report?
Precision System Science Co.,Ltd (7707) AI Stock Analysis
Precision System Science Co.,Ltd
(TSE/TYO:7707)
The overall score reflects an attractive valuation profile, bullish short-to-medium-term technical momentum, and a successful early operational turnaround supported by a highly resilient balance sheet. However, the score's upside is heavily constrained by significant cash flow weaknesses, specifically poor cash conversion, which presents underlying liquidity risks. Earnings call and corporate events data were unavailable and excluded from this analysis.
Precision System Science Co.,Ltd (7707) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.33B
- Dividend Yield
- 1.04%
- Average Volume (3M)
- 148.65K
- Price to Earnings (P/E)
- 13.3
- Beta (1Y)
- 1.02
- Revenue Growth
- 11.17%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 129
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Diagnostics & Research
Precision System Science Co.,Ltd Business Overview & Revenue Model
Company Description
Precision System Science Co., Ltd. (PSS), along with its subsidiaries, specializes in the development, production, and global distribution of automated and physicochemical instruments, software, and various related goods, serving both the Japanese do...
Precision System Science Co.,Ltd Financial Statement Overview
Summary
The company shows a commendable operational turnaround with returning top-line growth and a strong balance sheet characterized by low leverage. However, this is significantly offset by poor cash flow conversion and negative free cash flow, highlighting ongoing liquidity concerns.
Income Statement
75PositiveBalance Sheet
82Very PositiveCash Flow
42Neutral| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.22B | 5.22B | 4.69B | 3.98B | 5.28B | 7.43B |
| Gross Profit | 1.58B | 1.58B | 1.38B | 950.38M | 1.35B | 2.49B |
| EBITDA | 411.95M | 409.05M | 10.06M | -661.75M | -594.05M | 740.33M |
| Net Income | 394.87M | 394.87M | -253.10M | -1.12B | -1.32B | 45.34M |
Balance Sheet | ||||||
| Total Assets | 5.85B | 5.85B | 4.94B | 6.40B | 9.76B | 11.41B |
| Cash, Cash Equivalents and Short-Term Investments | 1.37B | 1.37B | 1.04B | 1.92B | 2.45B | 2.76B |
| Total Debt | 1.03B | 1.03B | 564.21M | 1.37B | 3.88B | 4.03B |
| Total Liabilities | 1.76B | 1.76B | 1.18B | 2.25B | 4.54B | 4.90B |
| Stockholders Equity | 4.09B | 4.09B | 3.76B | 4.14B | 5.22B | 6.51B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -50.57M | 43.24M | -130.81M | -162.03M | -1.38B |
| Operating Cash Flow | 0 | 51.41M | 95.83M | -106.80M | -6.75M | 869.16M |
| Investing Cash Flow | 0 | -98.03M | -8.24M | 2.06B | -213.70M | -2.29B |
| Financing Cash Flow | 0 | 460.79M | -910.82M | -2.51B | -154.05M | 93.73M |
Precision System Science Co.,Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7707, the sentiment is Negative. The current price of 193.00 is below the 20-day moving average (MA) of 202.75, below the 50-day MA of 209.10, and below the 200-day MA of 217.88, indicating a bearish trend. The MACD of -6.11 indicates Positive momentum. The RSI at 39.00 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7707.
Precision System Science Co.,Ltd Peers Comparison
Overall Rating
JP:457081Outperform- JP:770768Neutral
JP:338667Neutral
JP:777644Neutral
JP:497843Neutral
JP:489242Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4570 | 81Outperform | JPY 9.16B | 23.72 | ― | 0.62% | 7.10% | 17.17% |
| JP:7707 | 68Neutral | JPY 5.31B | 13.32 | ― | 1.04% | 11.17% | ― |
| JP:3386 | 67Neutral | JPY 7.12B | 19.11 | ― | 4.07% | 7.17% | 36.23% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:7776 | 44Neutral | JPY 6.90B | -5.90 | ― | ― | -56.16% | 3.12% |
| JP:4978 | 43Neutral | JPY 11.97B | -24.40 | ― | ― | -18.71% | -246.54% |
| JP:4892 | 42Neutral | JPY 5.40B | -6.57 | ― | ― | 364.72% | 18.43% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7707 | Precision System Science Co.,Ltd | 193.00 | 3.00 | 1.58% | |
| JP:3386 | Cosmo Bio Co., Ltd. | 1228.00 | -71.26 | -5.48% | |
| JP:4570 | Immuno-Biological Laboratories Co., Ltd. | 974.00 | 275.99 | 39.54% | |
| JP:4892 | Cyfuse Biomedical K.K. | 545.00 | -36.00 | -6.20% | |
| JP:4978 | ReproCELL Inc. | 115.00 | -46.00 | -28.57% | |
| JP:7776 | CellSeed Inc. | 171.00 | -239.00 | -58.29% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 19, 2026